ATE531725T1 - Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen - Google Patents

Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen

Info

Publication number
ATE531725T1
ATE531725T1 AT08726179T AT08726179T ATE531725T1 AT E531725 T1 ATE531725 T1 AT E531725T1 AT 08726179 T AT08726179 T AT 08726179T AT 08726179 T AT08726179 T AT 08726179T AT E531725 T1 ATE531725 T1 AT E531725T1
Authority
AT
Austria
Prior art keywords
treatment
egfr
inhibitor
gene
respond
Prior art date
Application number
AT08726179T
Other languages
English (en)
Inventor
Patrick Muraca
Original Assignee
Nuclea Biomarkers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers Llc filed Critical Nuclea Biomarkers Llc
Application granted granted Critical
Publication of ATE531725T1 publication Critical patent/ATE531725T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
AT08726179T 2007-02-27 2008-02-27 Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen ATE531725T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90369407P 2007-02-27 2007-02-27
PCT/US2008/002602 WO2008106175A2 (en) 2007-02-27 2008-02-27 Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors

Publications (1)

Publication Number Publication Date
ATE531725T1 true ATE531725T1 (de) 2011-11-15

Family

ID=39716322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08726179T ATE531725T1 (de) 2007-02-27 2008-02-27 Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen

Country Status (6)

Country Link
US (4) US20080206777A1 (de)
EP (2) EP2413142B1 (de)
AT (1) ATE531725T1 (de)
DK (2) DK2413142T3 (de)
ES (2) ES2412432T3 (de)
WO (1) WO2008106175A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246546T3 (es) * 1997-12-12 2006-02-16 Digene Corporation Valoracion de enfermedades relacionadas con el virus de papiloma humano.
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
JP2011518333A (ja) * 2008-04-17 2011-06-23 キアジェン ゲイサーズバーグ インコーポレイテッド 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット
US8288520B2 (en) 2008-10-27 2012-10-16 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and system
EP2419522A4 (de) * 2009-04-17 2012-10-31 Glen Weiss Verfahren und kits zur prognose des therapieergebnisses von tyrosinkinasehemmern
US9797000B2 (en) 2009-05-01 2017-10-24 Qiagen Gaithersburg Inc. Non-target amplification method for detection of RNA splice-forms in a sample
EP2478087B1 (de) 2009-09-14 2017-01-18 QIAGEN Gaithersburg, Inc. Zusammensetzungen und verfahren zur rückgewinnung von nukleinsäuren oder proteinen aus in zytologischen medien fixierten gewebeproben
CN102822189B (zh) * 2010-01-29 2016-06-29 奇亚根盖瑟斯堡股份有限公司 用于核酸的序列特异性纯化和多重复合体分析(multiplex analysis)的方法和组合物
JP2013517803A (ja) 2010-01-29 2013-05-20 キアジェン ゲイサーズバーグ インコーポレイテッド サンプル中のｈｐｖの存在を決定および確認する方法
US20110208433A1 (en) * 2010-02-24 2011-08-25 Biodesix, Inc. Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples
JP2013528049A (ja) 2010-05-19 2013-07-08 キアゲン ガイサーズバーグ アイエヌシー． 核酸の配列特異的な精製及び多重分析のための方法及び組成物
WO2012094059A2 (en) * 2010-11-10 2012-07-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing early stage non-small cell lung cancer
US9885092B2 (en) 2011-02-24 2018-02-06 Qiagen Gaithersburg Inc. Materials and methods for detection of HPV nucleic acids
CN103926408A (zh) * 2014-04-30 2014-07-16 天津医科大学肿瘤医院 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用
EP3612210A4 (de) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Manipulierte antigenrezeptoren exprimierende immunzellen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US6482795B1 (en) * 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1999001559A1 (fr) * 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Nouvelle kinase mapk
CA2318789C (en) 1998-02-25 2011-05-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6582946B1 (en) * 2001-03-12 2003-06-24 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6727072B2 (en) * 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
AU2003238871B2 (en) * 2002-06-05 2009-04-23 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
US8129125B2 (en) 2012-03-06
ES2412432T3 (es) 2013-07-11
WO2008106175A2 (en) 2008-09-04
WO2008106175A3 (en) 2008-11-20
ES2376978T3 (es) 2012-03-21
EP2114990B1 (de) 2011-11-02
DK2413142T3 (da) 2013-07-22
US20090263819A1 (en) 2009-10-22
EP2114990A2 (de) 2009-11-11
DK2114990T3 (da) 2012-01-16
EP2413142B1 (de) 2013-06-05
US20110189691A1 (en) 2011-08-04
DK2114990T5 (da) 2012-05-07
US8088589B2 (en) 2012-01-03
EP2413142A1 (de) 2012-02-01
EP2114990A4 (de) 2010-04-07
EP2114990B9 (de) 2012-03-28
US20080206777A1 (en) 2008-08-28
US20120094311A1 (en) 2012-04-19
US8900820B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
ATE531725T1 (de) Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
BR112017006088A2 (pt) uso de painéis de genes fgfr mutantes na identificação de pacientes com câncer que serão responsivos ao tratamento com um inibidor de fgfr
Gu et al. Correlation between reversal of DNA methylation and clinical symptoms in psoriatic epidermis following narrow-band UVB phototherapy
BRPI0518086A (pt) métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
WO2006091776A3 (en) Biomarkers for predicting prostate cancer progression
WO2009015233A3 (en) Gefitinib sensitivity-related gene expression and products and methods related thereto
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
ATE541946T1 (de) Verfahren und system zur bestimmung von genkopiezahlvarianten
Marino et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
BR112012030838A2 (pt) molécula de ácido nucléico isolada que codifica uma proteína mek1 mutante tendo atividade de mek1, vetor de expressão, célula hospedeira, método de produzir uma prote ína mek1 mutante, proteína mek1 mutante isolada, método de identificar um paciente que tem câncer, método de orimizar o tratamento de um paciente que tem câncer,e, uso de um inibidor de raf e de um inibidor de mek.
WO2012119113A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
BRPI0907637A8 (pt) biomarcadores p53
WO2008148115A8 (en) Methods, systems, and kits for evaluating multiple sclerosis
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
CA3126305A1 (en) Method and system for personalized, molecular based health management and digital consultation and treatment
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2013056087A3 (en) Compositions and methods for treating and preventing coronary heart disease
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
SI2838998T1 (en) EGFR AND ROS1 PRI CRAK
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso